Roche's 2021 sales up by 8% to 62.8B Swiss francs
Roche Holding AG announced on Thursday that its sales in the fiscal year 2021 advanced by 8% in comparison to 2020 to come in at 62.8 billion Swiss francs, exceeding expectations. The company's diluted earnings per share (EPS) saw an annual rise of 3% to stand at 19.81 Swiss francs per share. On the other hand, its net income declined by 1% year-on-year to land at 14.93 billion Swiss francs.
Meanwhile, Roche's sales in the fourth quarter of the fiscal year 2021 observed an annual increase of 12% to reach 16.12 billion Swiss francs.
"We achieved good results in 2021. The demand for our new medicines and diagnostics remains very high. [...] Based on our strong product portfolio in both divisions and the promising product pipeline, we are well positioned for future growth," Roche's Chief Executive Officer (CEO) Severin Schwan commented on the results.